Index - P/E - EPS (ttm) -0.66 Insider Own 0.12% Shs Outstand 56.93M Perf Week 7.14%
Market Cap 145.17M Forward P/E 10.20 EPS next Y 0.25 Insider Trans 0.00% Shs Float 56.86M Perf Month 10.87%
Income -39.21M PEG - EPS next Q -0.01 Inst Own 28.59% Short Float 4.84% Perf Quarter 13.33%
Sales 1.24B P/S 0.12 EPS this Y 77.74% Inst Trans -7.35% Short Ratio 4.22 Perf Half Y -6.59%
Book/sh 9.56 P/B 0.27 EPS next Y 621.21% ROA -2.67% Short Interest 2.75M Perf Year -46.54%
Cash/sh 7.61 P/C 0.34 EPS next 5Y 3.46% ROE -6.73% 52W Range 1.90 - 5.35 Perf YTD -6.93%
Dividend Est. - P/FCF - EPS past 5Y - ROI -5.68% 52W High -52.34% Beta 0.50
Dividend TTM - Quick Ratio 1.58 Sales past 5Y 9.98% Gross Margin 72.29% 52W Low 34.21% ATR (14) 0.14
Dividend Ex-Date - Current Ratio 1.94 EPS Y/Y TTM 58.40% Oper. Margin -3.34% RSI (14) 57.02 Volatility 5.17% 5.13%
Employees 7827 Debt/Eq 0.67 Sales Y/Y TTM -0.29% Profit Margin -3.16% Recom 1.70 Target Price 3.38
Option/Short Yes / Yes LT Debt/Eq 0.20 EPS Q/Q 83.64% Payout - Rel Volume 1.11 Prev Close 2.44
Sales Surprise -0.65% EPS Surprise -132.47% Sales Q/Q 7.21% Earnings Mar 21 BMO Avg Volume 652.65K Price 2.55
SMA20 8.19% SMA50 4.12% SMA200 -16.29% Trades
Volume 722,615 Change 4.51%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-26-24 Downgrade China Renaissance
Buy → Hold
Feb-08-24 Upgrade Daiwa Securities
Outperform → Buy
Feb-27-23 Upgrade CLSA
Underperform → Outperform
$4.40 → $7
Jan-30-23 Initiated JP Morgan
Overweight
Jan-11-23 Upgrade JP Morgan
Neutral → Overweight
$9 → $10
May-16-22 Upgrade JP Morgan
Underweight → Neutral
$5 → $8
Mar-14-22 Downgrade JP Morgan
Overweight → Underweight
$5
Mar-11-22 Upgrade Credit Suisse
Underperform → Neutral
$8.30
Dec-02-21 Downgrade CLSA
Buy → Outperform
Aug-20-21 Downgrade Daiwa Securities
Buy → Neutral
$42 → $20
Jul-23-21 Downgrade Credit Suisse
Outperform → Underperform
Jun-08-21 Resumed JP Morgan
Overweight
$45
May-19-21 Upgrade Credit Suisse
Neutral → Outperform
$41
Jan-25-21 Upgrade CLSA
Outperform → Buy
$42
Nov-24-20 Downgrade Credit Suisse
Outperform → Neutral
Jun-03-20 Upgrade Credit Suisse
Neutral → Outperform
$36
Mar-31-20 Downgrade BofA/Merrill
Buy → Neutral
Nov-22-19 Downgrade Credit Suisse
Outperform → Neutral
Aug-22-19 Downgrade CLSA
Buy → Outperform
Aug-05-19 Initiated Jefferies
Buy
Show Previous Ratings
Apr-19-24 07:13AM
06:34AM
06:26AM
06:00AM
Mar-26-24 08:51AM
12:45PM
Loading…
Mar-21-24 12:45PM
10:53AM
06:00AM
Mar-07-24 04:32PM
05:00AM
Feb-16-24 03:15AM
Jan-24-24 06:00AM
Nov-24-23 08:44AM
Nov-22-23 10:45AM
05:00AM
05:00AM
Loading…
Nov-08-23 05:00AM
Oct-05-23 05:17PM
Aug-29-23 08:12AM
Aug-28-23 03:39PM
01:00PM
12:37PM
06:00AM
Aug-14-23 06:00AM
Jul-14-23 10:22AM
Jun-27-23 04:18PM
Jun-15-23 08:20AM
Jun-02-23 11:54AM
May-25-23 02:47PM
01:30PM
06:00AM
06:00AM
Loading…
May-15-23 06:00AM
May-12-23 06:00AM
Apr-29-23 08:34AM
Apr-25-23 06:34AM
06:27AM
06:19AM
Mar-25-23 08:41AM
Mar-24-23 07:15AM
06:42AM
Mar-22-23 12:18PM
10:08AM
06:30AM
Mar-08-23 06:00AM
Mar-05-23 09:00AM
Feb-10-23 02:55PM
Feb-01-23 12:20PM
Jan-31-23 07:00PM
Jan-20-23 05:14AM
Dec-12-22 07:30AM
Dec-10-22 07:36AM
Dec-06-22 07:50AM
Dec-05-22 07:30AM
Nov-30-22 12:43PM
Nov-29-22 04:30PM
04:02PM
(Investor's Business Daily)
07:48AM
06:30AM
(Thomson Reuters StreetEvents)
05:00AM
Nov-28-22 08:07AM
Nov-16-22 05:30AM
Nov-14-22 09:22AM
(American City Business Journals)
Nov-11-22 09:00PM
Nov-10-22 08:43AM
(American City Business Journals) +9.04%
Nov-08-22 11:03AM
07:27AM
(The Wall Street Journal)
05:46AM
01:31AM
Nov-07-22 07:30PM
Oct-31-22 07:30PM
Oct-21-22 06:49AM
Oct-05-22 06:00AM
Sep-14-22 08:54AM
Sep-01-22 05:05AM
Aug-23-22 07:41PM
03:30PM
12:31PM
08:28AM
08:00AM
(Thomson Reuters StreetEvents)
07:49AM
06:00AM
Aug-22-22 08:35AM
Aug-09-22 07:00AM
Aug-08-22 08:52AM
Jun-27-22 07:00AM
Jun-24-22 07:23AM
Jun-09-22 09:25AM
(Yahoo Finance Video) -10.97%
Jun-08-22 01:50PM
May-27-22 07:46AM
07:00AM
May-26-22 05:30PM
04:04PM
(Investor's Business Daily)
02:30PM
10:19AM
06:00AM
May-17-22 05:38PM
07:00AM
May-12-22 07:00AM
May-05-22 06:30AM
May-04-22 06:11AM
May-02-22 06:00AM
Baozun, Inc. operates as an holding company, which through its subsidiaries provides brand electronic commerce (e-commerce) services and solutions. Its services include apparel and accessories; appliances; electronics; home and furnishings; food and health products; beauty and cosmetics; fast moving consumer goods, and mother and baby products; and insurance and automobiles. The company was founded by Wen Bin Qiu, Jun Hua Wu, and Qing Yu Zhang in August 2007 and is headquartered in Shanghai, China.
Index RUT P/E 11.42 EPS (ttm) 8.42 Insider Own 12.91% Shs Outstand 23.58M Perf Week 1.10%
Market Cap 2.27B Forward P/E 8.10 EPS next Y 11.87 Insider Trans -1.31% Shs Float 20.53M Perf Month -15.52%
Income 199.23M PEG 0.77 EPS next Q 1.06 Inst Own 87.11% Short Float 10.90% Perf Quarter -18.35%
Sales 2.36B P/S 0.96 EPS this Y 11.11% Inst Trans -2.46% Short Ratio 10.73 Perf Half Y 9.68%
Book/sh 78.71 P/B 1.22 EPS next Y 26.85% ROA 6.10% Short Interest 2.24M Perf Year -15.63%
Cash/sh 2.08 P/C 46.30 EPS next 5Y 14.83% ROE 11.39% 52W Range 84.15 - 141.91 Perf YTD -27.77%
Dividend Est. - P/FCF - EPS past 5Y 6.19% ROI 6.41% 52W High -32.22% Beta 1.85
Dividend TTM - Quick Ratio 0.30 Sales past 5Y 11.54% Gross Margin 22.99% 52W Low 14.29% ATR (14) 3.76
Dividend Ex-Date - Current Ratio 10.66 EPS Y/Y TTM -39.02% Oper. Margin 9.89% RSI (14) 38.48 Volatility 3.41% 3.39%
Employees 1089 Debt/Eq 0.68 Sales Y/Y TTM 2.35% Profit Margin 8.45% Recom 3.29 Target Price 115.88
Option/Short Yes / Yes LT Debt/Eq 0.67 EPS Q/Q 51.24% Payout 0.00% Rel Volume 1.26 Prev Close 93.92
Sales Surprise -8.36% EPS Surprise -13.73% Sales Q/Q 24.61% Earnings Apr 30 BMO Avg Volume 208.72K Price 96.18
SMA20 -5.96% SMA50 -12.46% SMA200 -17.16% Trades
Volume 263,112 Change 2.41%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-02-24 Downgrade Wedbush
Neutral → Underperform
$88 → $74
Oct-02-23 Upgrade BTIG Research
Sell → Neutral
Jun-14-23 Initiated Seaport Research Partners
Buy
$156
Feb-22-23 Downgrade BTIG Research
Neutral → Sell
$73
Apr-20-22 Upgrade BTIG Research
Sell → Neutral
Mar-23-22 Downgrade BTIG Research
Neutral → Sell
$98
Dec-09-21 Upgrade Wells Fargo
Underweight → Equal Weight
$125 → $160
Apr-16-21 Initiated Wells Fargo
Underweight
$150
Feb-22-21 Initiated KeyBanc Capital Markets
Sector Weight
Dec-09-20 Initiated UBS
Buy
$140
Nov-17-20 Downgrade JP Morgan
Neutral → Underweight
$129
Aug-05-20 Downgrade Wells Fargo
Overweight → Equal Weight
$122
Jul-21-20 Upgrade BTIG Research
Sell → Neutral
Jul-14-20 Resumed JMP Securities
Mkt Outperform
$120
Jun-04-20 Downgrade Wedbush
Outperform → Neutral
Apr-06-20 Upgrade Wedbush
Neutral → Outperform
$55
Mar-18-20 Downgrade JP Morgan
Neutral → Underweight
$39
Sep-11-19 Downgrade JP Morgan
Overweight → Neutral
$77 → $84.50
Aug-07-19 Downgrade BTIG Research
Neutral → Sell
$62
Jan-07-19 Upgrade Wells Fargo
Market Perform → Outperform
Show Previous Ratings
Today 10:01AM
Apr-22-24 06:11PM
Apr-19-24 10:56PM
Apr-18-24 08:38AM
Apr-16-24 08:00AM
07:30PM
Loading…
Apr-12-24 07:30PM
Apr-03-24 05:04PM
Apr-02-24 06:53PM
06:51PM
04:40PM
01:32PM
Mar-30-24 11:49PM
Mar-27-24 03:45PM
Mar-18-24 06:47PM
Mar-16-24 06:26PM
04:39PM
Loading…
Mar-14-24 04:39PM
Mar-11-24 04:03PM
Mar-07-24 02:39AM
Mar-05-24 04:47PM
Mar-04-24 01:11PM
Mar-01-24 11:09AM
Feb-29-24 06:16PM
Feb-27-24 10:02AM
Feb-21-24 08:39AM
08:36AM
02:54AM
(Thomson Reuters StreetEvents)
Feb-20-24 03:15PM
12:38PM
09:30AM
08:52AM
07:19AM
Loading…
07:19AM
(Associated Press Finance)
07:00AM
Feb-16-24 12:45PM
Feb-14-24 06:37AM
Feb-13-24 01:31PM
Feb-08-24 11:48AM
Feb-05-24 05:21PM
12:36PM
Feb-01-24 11:49AM
Jan-26-24 05:15AM
Jan-21-24 09:12AM
Jan-04-24 04:01PM
Dec-28-23 11:10AM
Dec-20-23 05:56PM
Dec-16-23 03:16AM
Dec-14-23 04:30PM
Dec-05-23 05:02PM
03:37PM
Nov-26-23 10:22AM
Nov-17-23 05:01PM
Nov-16-23 08:42AM
Nov-09-23 04:30PM
Nov-03-23 05:05PM
11:33AM
Nov-01-23 08:54AM
04:21AM
(Thomson Reuters StreetEvents)
Oct-31-23 05:30PM
10:33AM
09:30AM
08:25AM
07:17AM
(Associated Press Finance)
07:00AM
Oct-30-23 01:52PM
Oct-24-23 10:00AM
Oct-12-23 10:59AM
Oct-10-23 08:00AM
Oct-07-23 06:49AM
Oct-05-23 11:43AM
Oct-04-23 05:00PM
Oct-02-23 05:00PM
Sep-26-23 08:00AM
(Investor's Business Daily)
07:00AM
Sep-24-23 07:33PM
Sep-20-23 10:00AM
Sep-19-23 08:20AM
(Investor's Business Daily)
Sep-18-23 02:37PM
07:00AM
Sep-15-23 11:50AM
Sep-12-23 04:30PM
Sep-06-23 05:51PM
Sep-01-23 09:51AM
Aug-31-23 07:00AM
Aug-29-23 09:55AM
Aug-28-23 07:00AM
Aug-24-23 09:06AM
07:00AM
Aug-22-23 07:00AM
Aug-18-23 12:58PM
07:16AM
Aug-17-23 07:00AM
Aug-15-23 07:00AM
Aug-10-23 07:00AM
Aug-08-23 07:00AM
Aug-07-23 06:31AM
Aug-03-23 06:01PM
Aug-02-23 04:19AM
(Thomson Reuters StreetEvents)
Aug-01-23 04:00PM
09:30AM
08:25AM
07:20AM
LGI Homes, Inc. engages in the design, construction, marketing, and sale of new homes. It focuses on the residential land development business. It operates through the following segments: Central, West, Southeast, Florida, Midwest, Mid-Atlantic, and Northwest. The company was founded by Eric Thomas Lipar in 2003 and is headquartered in The Woodlands, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Lipar Eric Thomas CEO and Chairman of the Board Mar 11 '24 Sale 111.95 10,869 1,216,793 627,430 Mar 12 05:56 PM Snider Michael Larry President and COO Mar 11 '24 Sale 110.06 7,993 879,724 19,016 Mar 12 05:58 PM Merdian Charles Michael CFO and Treasurer Mar 11 '24 Sale 111.95 6,361 712,118 9,458 Mar 12 05:58 PM Garber Scott James General Counsel and Secretary Mar 11 '24 Sale 111.95 1,212 135,684 13,824 Mar 12 05:55 PM Smith Steven Randal Director Dec 21 '23 Sale 132.14 1,490 196,889 1,221 Dec 26 04:38 PM Snider Michael Larry President and COO Nov 20 '23 Sale 121.12 12,445 1,507,348 180,451 Nov 21 04:22 PM
Index NDX, S&P 500 P/E 29.15 EPS (ttm) 13.89 Insider Own 0.30% Shs Outstand 257.70M Perf Week 2.72%
Market Cap 104.59B Forward P/E 22.28 EPS next Y 18.17 Insider Trans -16.40% Shs Float 257.54M Perf Month -2.59%
Income 3.62B PEG 2.28 EPS next Q 4.08 Inst Own 94.26% Short Float 1.54% Perf Quarter -7.91%
Sales 9.84B P/S 10.63 EPS this Y 8.56% Inst Trans 1.21% Short Ratio 3.27 Perf Half Y 11.90%
Book/sh 68.22 P/B 5.94 EPS next Y 9.90% ROA 17.56% Short Interest 3.98M Perf Year 22.30%
Cash/sh 43.44 P/C 9.32 EPS next 5Y 12.80% ROE 22.99% 52W Range 316.43 - 448.40 Perf YTD -0.49%
Dividend Est. - P/FCF 31.34 EPS past 5Y 11.42% ROI 19.77% 52W High -9.70% Beta 0.38
Dividend TTM - Quick Ratio 3.78 Sales past 5Y 27.16% Gross Margin 87.17% 52W Low 27.96% ATR (14) 7.36
Dividend Ex-Date - Current Ratio 3.99 EPS Y/Y TTM 8.28% Oper. Margin 38.33% RSI (14) 49.94 Volatility 1.68% 1.69%
Employees 5400 Debt/Eq 0.05 Sales Y/Y TTM 12.47% Profit Margin 36.79% Recom 1.94 Target Price 464.96
Option/Short Yes / Yes LT Debt/Eq 0.04 EPS Q/Q 18.03% Payout 0.00% Rel Volume 0.87 Prev Close 399.92
Sales Surprise 0.19% EPS Surprise 3.27% Sales Q/Q 12.00% Earnings May 06 AMC Avg Volume 1.21M Price 404.91
SMA20 0.04% SMA50 -2.02% SMA200 5.89% Trades
Volume 1,061,870 Change 1.25%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-11-24 Upgrade Evercore ISI
In-line → Outperform
$438
Feb-15-24 Initiated Wolfe Research
Outperform
$515
Feb-06-24 Downgrade Evercore ISI
Outperform → In-line
$436 → $438
Feb-02-24 Downgrade Bernstein
Outperform → Mkt Perform
Jan-31-24 Downgrade Robert W. Baird
Neutral → Underperform
$325
Jan-31-24 Downgrade Maxim Group
Buy → Hold
Jan-24-24 Downgrade Canaccord Genuity
Hold → Sell
$332 → $379
Dec-14-23 Reiterated RBC Capital Mkts
Sector Perform
$347 → $379
May-30-23 Initiated William Blair
Outperform
$382
May-04-23 Resumed Piper Sandler
Overweight
$385
Mar-21-23 Initiated Bernstein
Outperform
$344
Jan-18-23 Initiated Canaccord Genuity
Hold
$311
Jan-17-23 Upgrade SVB Leerink
Mkt Perform → Outperform
$374
Dec-19-22 Downgrade Jefferies
Buy → Hold
$340
Jul-13-22 Initiated Cantor Fitzgerald
Overweight
$365
Jun-01-22 Upgrade Maxim Group
Hold → Buy
$325
May-23-22 Initiated SVB Leerink
Mkt Perform
$265
May-06-22 Downgrade Robert W. Baird
Outperform → Neutral
$250
May-03-22 Upgrade Morgan Stanley
Underweight → Equal-Weight
$250
Feb-03-22 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$269
Show Previous Ratings
Today 08:09AM
06:05AM
12:45AM
Apr-22-24 11:10AM
09:03AM
07:16AM
Loading…
07:16AM
05:52AM
Apr-20-24 09:45AM
06:48AM
Apr-19-24 05:50PM
11:57AM
04:30AM
Apr-18-24 08:30AM
08:00AM
07:00AM
06:00PM
Loading…
Apr-16-24 06:00PM
09:30AM
Apr-15-24 12:00PM
(Associated Press Finance)
09:15AM
09:04AM
Apr-13-24 08:47AM
05:29AM
Apr-12-24 10:55AM
(The Wall Street Journal)
Apr-11-24 04:29PM
04:18PM
(Investor's Business Daily)
01:59PM
(The Wall Street Journal)
11:58AM
11:03AM
09:47AM
09:39AM
09:15AM
Loading…
09:15AM
07:34AM
06:17AM
02:00AM
Apr-10-24 10:34PM
07:05PM
06:00PM
05:47PM
(The Wall Street Journal)
05:14PM
(Investor's Business Daily)
04:19PM
04:16PM
04:06PM
04:01PM
01:34PM
Apr-09-24 04:05PM
10:07AM
10:00AM
07:37AM
06:35AM
Apr-05-24 09:30AM
Apr-03-24 08:02PM
07:00PM
10:00AM
Apr-02-24 11:26AM
Apr-01-24 05:50PM
11:00AM
09:00AM
08:23AM
08:00AM
04:30AM
Mar-31-24 09:15AM
06:30AM
Mar-30-24 06:50AM
Mar-28-24 04:10PM
(Investor's Business Daily)
09:30AM
Mar-26-24 06:44AM
Mar-25-24 05:50PM
09:10AM
Mar-24-24 10:08AM
Mar-22-24 12:09PM
Mar-21-24 08:00AM
Mar-20-24 01:49PM
Mar-19-24 02:58PM
Mar-18-24 05:50PM
Mar-17-24 09:50AM
09:00AM
08:54AM
Mar-16-24 08:45AM
Mar-14-24 08:15AM
Mar-13-24 07:56AM
(Thomson Reuters StreetEvents)
Mar-12-24 05:50PM
Mar-09-24 05:52AM
Mar-06-24 02:45PM
11:30AM
Mar-05-24 09:30AM
06:28AM
Mar-04-24 04:09PM
11:02AM
09:18AM
Mar-02-24 09:30AM
Mar-01-24 05:30AM
(The Wall Street Journal)
01:59AM
Feb-29-24 11:26AM
09:00AM
Feb-28-24 11:15PM
(Thomson Reuters StreetEvents)
03:34PM
07:35AM
Feb-27-24 05:03AM
Feb-26-24 08:50AM
05:52AM
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Ambrose Kristen SVP & Chief Accounting Officer Apr 02 '24 Sale 419.00 240 100,560 7,500 Apr 03 04:02 PM Arbuckle Stuart A EVP, COO Feb 26 '24 Sale 425.70 5,034 2,142,974 49,691 Feb 27 04:37 PM ALTSHULER DAVID EVP, Global Research and CSO Feb 26 '24 Sale 425.70 4,239 1,804,542 25,813 Feb 27 04:24 PM Sachdev Amit EVP Chief Patient & Ext Af Off Feb 26 '24 Sale 425.70 3,004 1,278,803 55,325 Feb 27 04:59 PM Ambrose Kristen SVP & Chief Accounting Officer Feb 26 '24 Sale 425.70 883 375,893 7,965 Feb 27 04:29 PM Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. Feb 26 '24 Sale 425.70 883 375,893 15,972 Feb 27 04:44 PM Tatsis Ourania EVP, Chief Reg. & Quality Off. Feb 26 '24 Sale 425.70 354 150,698 55,804 Feb 27 05:02 PM Arbuckle Stuart A EVP, COO Feb 21 '24 Sale 421.77 3,603 1,519,637 59,439 Feb 23 04:12 PM Sachdev Amit EVP Chief Patient & Ext Af Off Feb 21 '24 Sale 421.77 3,191 1,345,868 60,798 Feb 23 04:20 PM ALTSHULER DAVID EVP, Global Research and CSO Feb 21 '24 Sale 421.77 3,002 1,266,154 34,022 Feb 23 04:10 PM Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. Feb 21 '24 Sale 421.77 1,201 506,546 18,509 Feb 23 04:16 PM Tatsis Ourania EVP, Chief Reg. & Quality Off. Feb 21 '24 Sale 421.77 360 151,837 59,467 Feb 23 04:28 PM Arbuckle Stuart A EVP, COO Feb 20 '24 Sale 420.79 4,804 2,021,475 63,042 Feb 21 04:19 PM Sachdev Amit EVP Chief Patient & Ext Af Off Feb 20 '24 Sale 420.79 4,254 1,790,041 63,989 Feb 21 04:38 PM ALTSHULER DAVID EVP, Global Research and CSO Feb 20 '24 Sale 420.79 4,002 1,684,002 37,024 Feb 21 04:13 PM Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. Feb 20 '24 Sale 420.79 801 337,053 19,710 Feb 21 04:23 PM Tatsis Ourania EVP, Chief Reg. & Quality Off. Feb 20 '24 Sale 420.79 480 201,979 59,827 Feb 21 04:43 PM LEIDEN JEFFREY M Executive Chairman Feb 15 '24 Sale 419.16 4,655 1,951,190 17,896 Feb 16 04:07 PM LEIDEN JEFFREY M Executive Chairman Feb 14 '24 Sale 419.04 4,356 1,825,338 22,551 Feb 16 04:07 PM LEIDEN JEFFREY M Executive Chairman Feb 13 '24 Sale 419.13 737 308,899 26,907 Feb 14 04:04 PM Arbuckle Stuart A EVP, COO Feb 12 '24 Sale 420.24 4,295 1,804,931 75,718 Feb 13 04:51 PM Sachdev Amit EVP Chief Patient & Ext Af Off Feb 12 '24 Sale 420.24 3,222 1,354,013 74,364 Feb 13 05:15 PM ALTSHULER DAVID EVP, Global Research and CSO Feb 12 '24 Sale 420.24 3,145 1,321,655 47,588 Feb 13 04:46 PM LEIDEN JEFFREY M Executive Chairman Feb 12 '24 Sale 419.51 2,656 1,114,205 27,644 Feb 14 04:04 PM Biller Jonathan EVP and Chief Legal Officer Feb 12 '24 Sale 418.77 1,738 727,822 18,280 Feb 13 04:56 PM Ambrose Kristen SVP & Chief Accounting Officer Feb 12 '24 Sale 420.24 1,374 577,410 9,676 Feb 13 04:48 PM Atkinson Edward Morrow III EVP, Chief Technical Ops. Off. Feb 12 '24 Sale 420.24 913 383,679 23,137 Feb 13 04:54 PM LEIDEN JEFFREY M Executive Chairman Jan 08 '24 Sale 419.07 6,648 2,785,977 2,423 Jan 10 04:06 PM WAGNER CHARLES F JR EVP & Chief Financial Officer Jan 02 '24 Sale 405.00 3,000 1,215,000 43,693 Jan 04 04:17 PM Kewalramani Reshma CEO & President Dec 15 '23 Option Exercise 181.83 17,135 3,115,593 125,846 Dec 19 04:15 PM Kewalramani Reshma CEO & President Dec 15 '23 Sale 407.00 17,135 6,973,945 108,711 Dec 19 04:15 PM Arbuckle Stuart A EVP, COO Dec 13 '23 Option Exercise 187.53 8,603 1,613,321 65,159 Dec 15 04:20 PM LEIDEN JEFFREY M Executive Chairman Dec 13 '23 Sale 399.42 13,354 5,333,799 9,071 Dec 15 04:33 PM Arbuckle Stuart A EVP, COO Dec 13 '23 Sale 399.00 8,603 3,432,597 56,556 Dec 15 04:20 PM Kewalramani Reshma CEO & President Dec 13 '23 Sale 397.00 5,098 2,023,906 108,711 Dec 15 04:23 PM WAGNER CHARLES F JR EVP & Chief Financial Officer Nov 20 '23 Sale 349.88 3,000 1,049,640 46,693 Nov 21 04:07 PM Sachdev Amit EVP Chief Patient & Ext Af Off Nov 15 '23 Sale 369.92 35 12,947 58,814 Nov 17 04:16 PM ALTSHULER DAVID EVP, Global Research and CSO Nov 15 '23 Sale 369.92 19 7,028 32,038 Nov 17 04:11 PM Bozic Carmen EVP and CMO Nov 14 '23 Sale 380.82 5,650 2,151,633 29,302 Nov 16 04:15 PM Kewalramani Reshma CEO & President Nov 13 '23 Sale 377.00 5,097 1,921,569 113,809 Nov 15 04:16 PM SACHS BRUCE I Director Nov 06 '23 Option Exercise 127.54 11,250 1,434,825 51,250 Nov 08 04:11 PM SACHS BRUCE I Director Nov 06 '23 Sale 385.00 11,250 4,331,250 40,000 Nov 08 04:11 PM Bozic Carmen EVP and CMO Oct 31 '23 Sale 355.92 5,651 2,011,304 34,952 Nov 02 04:07 PM Bozic Carmen EVP and CMO Oct 17 '23 Sale 373.25 5,651 2,109,236 40,603 Oct 19 04:18 PM Bhatia Sangeeta N. Director Oct 17 '23 Sale 375.00 243 91,125 3,901 Oct 19 04:13 PM LEIDEN JEFFREY M Executive Chairman Oct 16 '23 Sale 374.00 12,962 4,847,788 22,425 Oct 18 04:17 PM Bhatia Sangeeta N. Director Oct 06 '23 Sale 360.00 242 87,120 4,144 Oct 11 04:14 PM Bozic Carmen EVP and CMO Oct 03 '23 Sale 345.28 5,651 1,951,177 46,254 Oct 05 04:30 PM Biller Jonathan EVP and Chief Legal Officer Oct 02 '23 Sale 346.76 610 211,524 10,569 Oct 03 04:07 PM Bozic Carmen EVP and CMO Sep 19 '23 Sale 351.00 5,651 1,983,501 51,905 Sep 21 04:15 PM Bozic Carmen EVP and CMO Sep 05 '23 Sale 352.66 5,651 1,992,882 57,556 Sep 07 04:29 PM Tatsis Ourania EVP, Chief Reg. & Quality Off. Aug 23 '23 Sale 355.00 2,500 887,500 48,637 Aug 25 04:14 PM Kearney Terrence C Director Aug 10 '23 Option Exercise 127.54 10,000 1,275,400 16,536 Aug 14 04:09 PM Sachdev Amit EVP, Chief Patient Officer Aug 10 '23 Sale 350.00 10,031 3,510,850 58,814 Aug 14 04:05 PM Kearney Terrence C Director Aug 10 '23 Sale 350.00 10,000 3,500,000 6,536 Aug 14 04:09 PM Tatsis Ourania EVP, Chief Reg. & Quality Off. Aug 10 '23 Sale 345.79 5,750 1,988,293 51,137 Aug 14 04:08 PM Bhatia Sangeeta N. Director Aug 09 '23 Sale 345.51 242 83,613 4,386 Aug 11 04:05 PM ALTSHULER DAVID EVP, Global Research and CSO Aug 09 '23 Sale 345.51 63 21,767 32,038 Aug 11 04:05 PM SACHS BRUCE I Director Jul 17 '23 Option Exercise 127.54 11,250 1,434,825 51,250 Jul 18 04:17 PM SACHS BRUCE I Director Jul 17 '23 Sale 356.75 11,250 4,013,459 40,000 Jul 18 04:17 PM Kewalramani Reshma CEO & President Jul 17 '23 Sale 355.00 7,828 2,778,940 118,906 Jul 18 04:13 PM Arbuckle Stuart A EVP, COO Jun 15 '23 Option Exercise 187.53 8,603 1,613,321 65,159 Jun 20 04:07 PM Arbuckle Stuart A EVP, COO Jun 15 '23 Sale 349.00 8,603 3,002,447 56,556 Jun 20 04:07 PM Ambrose Kristen SVP & Chief Accounting Officer May 30 '23 Sale 329.82 289 95,318 6,838 Jun 01 04:12 PM Arbuckle Stuart A EVP, COO May 30 '23 Sale 329.82 82 27,045 56,556 Jun 01 04:16 PM Sanna Bastiano EVP, Cell & Genetic Therapies May 08 '23 Sale 350.00 2,850 997,500 32,038 May 09 04:15 PM LEIDEN JEFFREY M Executive Chairman May 08 '23 Sale 349.00 1,125 392,625 35,387 May 09 04:10 PM LEIDEN JEFFREY M Executive Chairman May 05 '23 Sale 349.56 879 307,262 36,512 May 09 04:10 PM Sanna Bastiano EVP, Cell & Genetic Therapies May 05 '23 Sale 350.03 422 147,713 34,888 May 09 04:15 PM LEIDEN JEFFREY M Executive Chairman May 03 '23 Sale 350.11 4,508 1,578,301 37,391 May 04 04:50 PM Sanna Bastiano EVP, Cell & Genetic Therapies May 03 '23 Sale 350.74 2,781 975,418 35,310 May 04 04:51 PM LEIDEN JEFFREY M Executive Chairman May 02 '23 Sale 349.89 6,450 2,256,761 41,899 May 04 04:50 PM Sanna Bastiano EVP, Cell & Genetic Therapies May 02 '23 Sale 350.66 1,622 568,768 38,091 May 04 04:51 PM Bhatia Sangeeta N. Director May 02 '23 Sale 348.28 580 202,004 4,628 May 03 04:44 PM Kewalramani Reshma CEO & President Apr 27 '23 Sale 339.08 3,317 1,124,726 126,652 May 01 04:26 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
